Follow-Up Management for Long-Term Vyvanse (Lisdexamfetamine) Treatment
At follow-up visits for patients on long-term Vyvanse therapy, systematically assess ADHD symptom control, monitor for misuse/diversion, evaluate cardiovascular parameters (blood pressure, heart rate), track growth metrics (height, weight, BMI), screen for common side effects (appetite suppression, insomnia, psychiatric symptoms), and verify medication adherence.
Core Assessment Components
1. Symptom Control and Treatment Response
- Evaluate target ADHD symptoms using standardized rating scales (e.g., ADHD-RS-IV) from both patient and collateral sources 1
- Obtain reports from teachers/employers when applicable to assess functional improvement across settings 1
- For adolescents and adults, include self-ratings of symptom severity 1
- Assess functional outcomes beyond symptom scores—academic performance, work productivity, driving safety (particularly for adolescents), and interpersonal relationships 2
2. Medication Misuse and Diversion Screening
This is particularly critical given Vyvanse's Schedule II classification despite its lower abuse potential compared to immediate-release amphetamines.
- Monitor prescription refill patterns for early requests or inconsistent timing 2
- Screen for diversion behaviors: giving/selling medication to others, requests for dose escalation without clinical justification 2
- Assess for substance use, especially in adolescents and young adults—this includes alcohol, cannabis, and other stimulants 2
- Ask directly about methods of administration (patients should be taking medication orally as prescribed) 3
3. Cardiovascular Monitoring
Measure at every visit 3:
- Blood pressure and pulse rate—expect mean increases of 2-4 mmHg (BP) and 3-6 bpm (pulse) on stimulants 3
- Document potentially clinically important (PCI) elevations:
Reassess cardiac risk factors periodically, particularly if new symptoms emerge (chest pain, syncope, palpitations) 3
4. Growth Monitoring (Pediatric Patients)
Critical for children and adolescents given CNS stimulants' association with growth suppression 3:
- Measure height and weight at each visit 1
- Calculate and plot BMI percentiles 4
- Expected changes with long-term treatment (based on 2-year data): mean weight gain of only 2.1 kg, height increase of 6.1 cm, and BMI decrease of -0.5 kg/m² 4
- Watch for shifts to lower z-score categories for height, weight, and BMI—this occurred commonly in long-term studies 4
- Consider treatment interruption (drug holidays) if growth is not progressing as expected 3
5. Side Effect Assessment
Systematically ask about specific known side effects rather than general inquiries 1:
Most common treatment-emergent adverse events (from long-term studies):
- Decreased appetite (49.4% in pediatric studies)—typically onset at 13.5 days, duration 169 days 4
- Insomnia (13-19.5%)—onset at 17 days, duration 42.8 days 4, 5
- Weight loss (18.2%)—onset at 29 days, duration 225 days 4
- Headache (5.7-17.2%)—onset at 22 days, brief duration (2 days) 4, 5
- Irritability (8.6-11.2%) 4, 5
- Upper respiratory infections (21.8% in adults) 5
- Dry mouth (16.6% in adults) 5
Psychiatric symptoms requiring specific screening 3:
- Psychotic symptoms: hallucinations, paranoia, delusional thinking (rare: ~0.1% in pooled studies) 3
- Mood changes: mania, hypomania, increased aggression 3
- Suicidal ideation: occurred in 2 of 314 patients in 2-year pediatric study 4
- Tics: reported in 5.1% of long-term pediatric patients 4
Peripheral vasculopathy (Raynaud's phenomenon): Ask about digital color changes, numbness, or pain in fingers/toes 3
6. Medication Adherence Verification
- Review dosing schedule: Vyvanse should be taken once daily in the morning 3
- Confirm proper administration: swallowed whole or mixed with water/yogurt/orange juice (not stored after mixing) 3
- Assess timing: afternoon doses should be avoided due to insomnia risk 3
- Identify barriers: cost, forgetfulness, side effects, perceived lack of benefit
7. Dose Optimization
For patients with suboptimal response:
- Verify adherence first before dose adjustment
- Maximum recommended dose is 70 mg/day for ADHD 3
- Dose adjustments in renal impairment: maximum 50 mg/day for severe renal impairment (GFR 15-30), maximum 30 mg/day for ESRD 3
- Consider drug interactions affecting amphetamine levels (urinary pH modifiers) 3
Visit Frequency
Maintenance phase monitoring (after initial titration):
- Monthly visits initially until symptoms are stabilized 1
- Frequency should increase if there are concerning side effects, comorbid psychiatric conditions, adherence problems, or signs of misuse 1
- Long-term stable patients may transition to less frequent monitoring, but never eliminate systematic assessment of the core parameters above
Common Pitfalls to Avoid
Failing to obtain collateral information: Relying solely on patient self-report misses important functional outcomes, particularly in children and adolescents 1
Neglecting growth monitoring in pediatric patients: This is a black box concern requiring systematic tracking 3
Missing early signs of misuse: Adolescents are at highest risk for diversion; monitor refill patterns and screen for substance use 2
Inadequate cardiovascular monitoring: Small mean increases can mask clinically significant elevations in individual patients 3, 4
Dismissing psychiatric symptoms as "just ADHD": New-onset psychosis, mania, or suicidality requires immediate evaluation and potential medication discontinuation 3
Continuing ineffective treatment: If symptoms remain poorly controlled despite adequate dosing and adherence, consider switching medications or adding behavioral interventions rather than exceeding maximum doses 1